- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 159813, 6 pages
VEGF and bFGF Gene Polymorphisms in Patients with Non-Hodgkin's Lymphoma
1Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, L. Pasteura 4, 50-367 Wroclaw, Poland
2Department of Internal, Occupational Diseases and Hypertension, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland
3Laboratory of Clinical Immunogenetics and Pharmacogenetics, L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland
Received 14 April 2013; Revised 26 June 2013; Accepted 3 July 2013
Academic Editor: Konstantinos Papatheodorou
Copyright © 2013 Tomasz Wróbel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. Ribatti, A. Vacca, B. Nico, M. Fanelli, L. Roncali, and F. Dammacco, “Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study,” European Journal of Haematology, vol. 56, no. 1-2, pp. 45–53, 1996.
- C. L. Ho, L. F. Sheu, and C. Y. Li, “Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma,” Applied Immunohistochemistry and Molecular Morphology, vol. 10, no. 4, pp. 316–321, 2002.
- P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu, “Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients,” Blood, vol. 96, no. 12, pp. 3712–3718, 2000.
- V. Vincenti, C. Cassano, M. Rocchi, and M. G. Persico, “Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3,” Circulation, vol. 93, no. 8, pp. 1493–1495, 1996.
- I. J. Brogan, N. Khan, K. Isaac, J. A. Hutchinson, V. Pravica, and I. V. Hutchinson, “Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene,” Human Immunology, vol. 60, no. 12, pp. 1245–1249, 1999.
- T. Awata, K. Inoue, S. Kurihara et al., “A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes,” Diabetes, vol. 51, no. 5, pp. 1635–1639, 2002.
- A. Stevens, J. Soden, P. E. Brenchley, S. Ralph, and D. W. Ray, “Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter,” Cancer Research, vol. 63, no. 4, pp. 812–816, 2003.
- D. Ray, M. Mishra, S. Ralph, I. Read, R. Davies, and P. Brenchley, “Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes,” Diabetes, vol. 53, no. 3, pp. 861–864, 2004.
- C. J. Watson, N. J. A. Webb, M. J. Bottomley, and P. E. C. Brenchley, “Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production,” Cytokine, vol. 12, no. 8, pp. 1232–1235, 2000.
- W. Renner, S. Kotschan, C. Hoffmann, B. Obermayer-Pietsch, and E. Pilger, “A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels,” Journal of Vascular Research, vol. 37, no. 6, pp. 443–448, 2000.
- M. Lafage-Pochitaloff, F. Galland, J. Simonetti, H. Prats, M. G. Mattei, and D. Birnbaum, “The human basic fibroblast growth factor gene is located on the long arm of chromosome 4 at bands q26-q27,” Oncogene Research, vol. 5, no. 3, pp. 241–244, 1990.
- M. . Beránek, S. Tschöplová, K. Kanková, V. Kuhrová, and J. Vácha, “Genetic variation in the promoter region of the basic fibroblast growth factor gene,” Human Immunology, vol. 64, no. 3, pp. 374–377, 2003.
- D. Papazoglou, G. Galazios, K. Papatheodorou et al., “Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss,” Fertility and Sterility, vol. 83, no. 4, pp. 959–963, 2005.
- S. Galimberti, B. Nagy, G. A. Palumbo et al., “Vascular endothelial growth factor polymorphisms in mantle cell lymphoma,” Acta Haematologica, vol. 123, no. 2, pp. 91–95, 2010.
- S. Kariž, D. Grabar, M. Krkovič, J. Osredkar, and D. Petrovič, “Polymorphisms in the promoter region of the basic fibroblast growth factor gene are not associated with myocardial infarction in a slovene population with type 2 diabetes,” Journal of International Medical Research, vol. 37, no. 5, pp. 1596–1603, 2009.
- M. G. Petrovič, M. Krkovič, J. Osredkar, M. Hawlina, and D. Petrovič, “Polymorphisms in the promoter region of the basic fibroblast growth factor gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes,” Clinical and Experimental Ophthalmology, vol. 36, no. 2, pp. 168–172, 2008.
- B. Hazar, S. Paydas, S. Zorludemir, B. Sahin, and I. Tuncer, “Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma,” Leukemia and Lymphoma, vol. 44, no. 12, pp. 2089–2093, 2003.
- S. Paydas, G. Seydaoglu, M. Ergin, S. Erdogan, and S. Yavuz, “The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas,” Leukemia and Lymphoma, vol. 50, no. 3, pp. 366–373, 2009.
- S. Klein, M. Roghani, and D. B. Rifkin, “Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action,” EXS, vol. 79, pp. 159–192, 1997.
- F. J. Giles, J. M. Vose, K. A. Do et al., “Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma,” Leukemia Research, vol. 28, no. 6, pp. 595–604, 2004.
- T. Wróbel, G. Mazur, L. Usnarska-Zubkiewicz, and K. Kuliczkowski, “Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients,” Polskie Archiwum Medycyny Wewnetrznej, vol. 112, no. 2, pp. 919–923, 2004.
- J. M. Jørgensen, F. B. Sørensen, K. Bendix et al., “Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas,” Leukemia and Lymphoma, vol. 50, no. 10, pp. 1647–1660, 2009.
- L. P. Diao, X. M. Yu, Y. H. Gao et al., “Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 11, pp. 1473–1481, 2009.
- M. K. Kim, C. Suh, H. S. Chi et al., “VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma,” Cancer Science, vol. 103, no. 3, pp. 497–503, 2012.
- T. Wróbel, M. Poreba, G. Mazur et al., “Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma,” Neoplasma, vol. 53, no. 3, pp. 253–258, 2006.
- A. T. Stopeck, J. M. Unger, L. M. Rimsza et al., “A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515,” Blood, vol. 120, no. 6, pp. 1210–1217, 2012.
- G. Mazur, K. Bogunia-Kubik, T. Wrobel, K. Kuliczkowski, and A. Lange, “TGF-β1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients,” Cytokine, vol. 33, no. 3, pp. 145–149, 2006.
- K. Bogunia-Kubik, G. Mazur, T. Wróbel, K. Kuliczkowski, and A. Lange, “Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma,” Tissue Antigens, vol. 71, no. 2, pp. 146–150, 2008.